These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 1666298)

  • 1. Phase II study of sulofenur (LY186641) in untreated patients with extensive small cell lung cancer.
    Shepherd FA; MacCormick R; Eisenhauer EA
    Ann Oncol; 1991; 2(10):772-3. PubMed ID: 1666298
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase II study of sulofenur (LY186641) in measurable metastatic renal cancer.
    Weinerman B; Eisenhauer E; Stewart D; Mertens W; Tannock I; Venner P; Spaulding R
    Ann Oncol; 1992 Jan; 3(1):83-4. PubMed ID: 1606075
    [No Abstract]   [Full Text] [Related]  

  • 3. A phase II study of sulofenur (LY186641) in gastric cancer.
    Kamthan A; Scarffe JH; Walling J; Hatty S; Peters B; Coleman R; Smyth JF
    Anticancer Drugs; 1992 Aug; 3(4):331-5. PubMed ID: 1421428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of sulofenur (LY186641) given orally on a daily x 21 schedule.
    Brown TD; O'Rourke TJ; Kuhn JG; Craig JB; Havlin K; Burris HA; Cagnola J; Hamilton JM; Grindey GB; Satterlee WG
    Anticancer Drugs; 1994 Apr; 5(2):151-9. PubMed ID: 8049498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of sulofenur (LY 186641). A novel antineoplastic agent in advanced non-small cell lung cancer.
    Munshi NC; Seitz DE; Fossella F; Lippman SM; Einhorn LH
    Invest New Drugs; 1993 Feb; 11(1):87-90. PubMed ID: 8394298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of sulofenur, a novel sulfonylurea, in recurrent epithelial ovarian cancer.
    O'Brien ME; Hardy J; Tan S; Walling J; Peters B; Hatty S; Wiltshaw E
    Cancer Chemother Pharmacol; 1992; 30(3):245-8. PubMed ID: 1628377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of the novel sulphonylurea sulofenur in advanced breast cancer.
    Talbot DC; Smith IE; Nicolson MC; Powles TJ; Button D; Walling J
    Cancer Chemother Pharmacol; 1993; 31(5):419-22. PubMed ID: 8431978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II evaluation of triazinate in patients with metastatic lung cancer.
    Creagan ET; Eagan RT; Fleming TR; Frytak S; Ingle JN; Kvols LK; Nichols WC
    Cancer Treat Rep; 1980; 64(10-11):1057-9. PubMed ID: 6257389
    [No Abstract]   [Full Text] [Related]  

  • 9. Phase II trial of AMSA in patients with refractory small cell carcinoma of the lung.
    Fuks JZ; Van Echo DA; Aisner J; Von Hoff D; Wiernik PH
    Cancer Treat Rep; 1981; 65(1-2):133-4. PubMed ID: 6261947
    [No Abstract]   [Full Text] [Related]  

  • 10. Evaluation of new drugs in untreated patients with small-cell lung cancer: its time has come.
    Ettinger DS
    J Clin Oncol; 1990 Mar; 8(3):374-7. PubMed ID: 2155306
    [No Abstract]   [Full Text] [Related]  

  • 11. A phase II trial of TCNU in patients with squamous, adeno and large cell carcinoma of the lung.
    Vibe-Petersen J; Bach F; Pedersen AG; Smyth J; Hansen HH
    Eur J Cancer Clin Oncol; 1989 Dec; 25(12):1881-5. PubMed ID: 2561100
    [No Abstract]   [Full Text] [Related]  

  • 12. Phase II study of 1,2,4-triglycidylurazol (TGU) in previously untreated and treated patients with small cell lung cancer.
    Lund B; Hansen F; Hansen M; Hansen HH
    Eur J Cancer Clin Oncol; 1987 Jul; 23(7):1031-3. PubMed ID: 2822424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity and clinical pharmacology of sulofenur in ovarian cancer.
    Taylor CW; Alberts DS; Peng YM; McCloskey TM; Matzner M; Roe DJ; Plezia PM; Grindey GB; Hamilton M; Seitz D
    J Natl Cancer Inst; 1992 Dec; 84(23):1798-802. PubMed ID: 1433369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Polyamines in the evaluation of the effectiveness of cancer patient treatment].
    Bassalyk LS; Nemtsova MP; Merabishvili NV; Tevzadze TA; Korbukh IA
    Vestn Akad Med Nauk SSSR; 1982; (3):57-61. PubMed ID: 6283759
    [No Abstract]   [Full Text] [Related]  

  • 15. A phase II clinical study of mAMSA in small cell carcinoma of the lung.
    Dady PJ; Sappino AP; Rudd A; Smith IE
    Cancer Chemother Pharmacol; 1981; 6(2):195-6. PubMed ID: 6273006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitoxantrone for treatment of patients with refractory small cell carcinoma of the lung: a Southwest Oncology Group Study.
    Von Hoff DD; Chen T; Clark GM; Callahan SK; Livingston R
    Cancer Treat Rep; 1983 Apr; 67(4):403-4. PubMed ID: 6303588
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase II trial of aziridinylbenzoquinone (AZQ) in patients with refractory small cell carcinoma of the lung.
    Fuks JZ; Aisner J; Van Echo DA; Levitt M; Ihde DC; Carney D; Wiernik PH
    Am J Clin Oncol; 1983 Apr; 6(2):171-3. PubMed ID: 6299094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl)-1-nitrosourea in small cell cancer of the lung.
    Chapman RA; Natale RB; Young CW; Wittes RE
    Am J Clin Oncol; 1984 Oct; 7(5):413-4. PubMed ID: 6095639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of tiazofurin (NSC 286193) in the treatment of advanced small cell bronchogenic carcinoma.
    Holoye PY; Carr DT; Dhingra HM; Glisson BS; Lee JS; Murphy WK; Umsawasdi T; Jeffries D
    Invest New Drugs; 1988 Sep; 6(3):217-8. PubMed ID: 2847992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New treatments for small cell lung cancer. When to test.
    Smith IE
    Chest; 1989 Jul; 96(1 Suppl):59S-61S. PubMed ID: 2544363
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.